Last reviewed · How we verify

NCT05437822

Tranexamic Acid in Proximal Humeral Fractures

Status unknown Phase 4 Last updated 5 July 2022
What this trial tests

Phase 4 trial testing Tranexamic acid in Proximal Humeral Fracture in 40 participants. Status unknown.

Timeline
29 June 2022
Primary endpoint
21 June 2023
24 June 2023

Quick facts

Lead sponsorElda University Hospital
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment40
Start date29 June 2022
Primary completion21 June 2023
Estimated completion24 June 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Elda University Hospital

Who can join

18 and older, any sex, with Proximal Humeral Fracture or Surgical Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the effect of tranexamic acid (on blood loss and transfusion requirements in patients with proximal humeral fractures requiring open surgical approaches. This a blinded, controlled, therapeutic trial in which the patients will be randomized to receive TXA or no drug intervention. The primary outcome is the estimated total blood loss. This study presents only minimal risks for the included patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

Other recruiting trials for Proximal Humeral Fracture

Currently open trials in the same condition.

Other Elda University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing